Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, MA, NJ, MD, CO · listed Sep 9, 2009 → Feb 15, 2024
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:57 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
3 of 82 offerings report sales commissions totalling $25,924,130; 2 report finder's fees totalling $704,015; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Dec 26, 2024 D File 021-533328 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 15, 2024 D File 021-505403 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 2, 2024 D File 021-504214 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 8, 2024 D File 021-501863 | $0 | $0 | $0 The Issuers are obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | Jun 1, 2023 D File 021-483102 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 26, 2023 D File 021-482711 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 18, 2023 D File 021-471087 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 18, 2023 D File 021-471093 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2022 D File 021-460364 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 29, 2022 D File 021-443816 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 6, 2022 D File 021-440697 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 19, 2022 D File 021-429972 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 15, 2021 D File 021-402903 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 4, 2021 D File 021-401803 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 29, 2021 D File 021-397664 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 14, 2021 D File 021-395770 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 28, 2021 D File 021-387726 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 19, 2021 D File 021-386679 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 14, 2021 D File 021-386398 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | Nov 30, 2020 D File 021-381671 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 30, 2020 D File 021-381672 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 25, 2020 D File 021-374057 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 14, 2020 D File 021-373217 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 12, 2020 D/A File 021-356331 | $0 | $486,000 | $0 | TripleTree, LLC BrokerCheck CRD 42820 ↗ |
| EDGAR ↗ | Mar 11, 2020 D File 021-362567 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 14, 2020 D/A File 021-334622 | $3,000,000 (est.) | $0 | $0 | Morgan Stanley & Co. LLC BrokerCheck CRD 8209 ↗ |
| EDGAR ↗ | Dec 11, 2019 D File 021-355311 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 16, 2019 D File 021-351154 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 2, 2019 D File 021-350167 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 15, 2019 D/A File 021-331081 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 15, 2019 D/A File 021-310430 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 17, 2018 D/A File 021-315270 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 17, 2018 D File 021-321524 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 7, 2018 D File 021-307149 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 7, 2018 D File 021-307152 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 20, 2017 D File 021-297147 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 22, 2017 D File 021-293279 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 4, 2017 D/A File 021-270759 | $15,908,222 | $218,015 | $0 | Morgan Stanley & Co. LLC BrokerCheck CRD 8209 ↗ N/A no CRD number reported via OUISA CAPITAL, LLC (CRD 102840 ↗) N/A no CRD number reported via Brooklands Capital Strategies BD, LP (CRD 281951 ↗) UBS Securities LLC BrokerCheck CRD 7654 ↗ Raptor International, LLC no CRD number reported |
| EDGAR ↗ | May 16, 2017 D File 021-286870 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 1, 2017 D File 021-281559 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 24, 2017 D File 021-281262 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 9, 2017 D File 021-280340 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | Jan 13, 2017 D File 021-278350 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 26, 2016 D/A File 021-210729 | $0 | $0 | $0 (est.) Proceeds will be used for general corporate purposes, including, but not limited to, executive salaries | None listed on this filing |
| EDGAR ↗ | Jun 14, 2016 D File 021-264954 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 18, 2015 D File 021-247873 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 6, 2014 D File 021-222342 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | May 20, 2014 D File 021-217689 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 7, 2014 D File 021-215047 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 21, 2014 D File 021-212315 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 13, 2013 D File 021-201262 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 22, 2013 D File 021-193796 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 10, 2013 D File 021-189883 | $7,015,908 | $0 | $0 | MORGAN STANLEY & CO. LLC BrokerCheck CRD 8209 ↗ |
| EDGAR ↗ | Jan 3, 2013 D File 021-189442 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 14, 2012 D File 021-188408 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 30, 2012 D/A File 021-147387 | $0 | $0 | $0 Working capital and general corporate purposes. | None listed on this filing |
| EDGAR ↗ | Aug 22, 2012 D File 021-183097 | $0 | $0 | $0 Working capital and general corporate purposes. | None listed on this filing |
| EDGAR ↗ | Aug 21, 2012 D File 021-183005 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 9, 2012 D File 021-177919 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 17, 2012 D File 021-171930 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2011 D File 021-170574 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 15, 2011 D File 021-170146 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 8, 2011 D File 021-168354 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 29, 2011 D File 021-163698 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 22, 2011 D/A File 021-145815 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 20, 2011 D/A File 021-117892 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 20, 2011 D File 021-158650 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 19, 2010 D File 021-150787 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 13, 2010 D File 021-148928 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 16, 2010 D File 021-145107 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 9, 2010 D File 021-144681 | $0 | $0 | $0 The investors are obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | Jul 9, 2010 D File 021-144685 | $0 | $0 | $0 The investors are obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | Jun 23, 2010 D File 021-143870 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 9, 2010 D File 021-143174 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 9, 2010 D File 021-143180 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 14, 2010 D File 021-142088 | $0 | $0 | $0 Proceeds will be used for working capital. | None listed on this filing |
| EDGAR ↗ | Apr 19, 2010 D File 021-140790 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 15, 2010 D/A File 021-56548 | $0 | $0 | $0 Proceeds will be used for working capital. | None listed on this filing |
| EDGAR ↗ | Nov 17, 2009 D File 021-123103 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 2, 2009 D/A File 021-102325 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 9, 2009 D File 021-117569 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 27, 2009 D File 021-104032 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Mythic Therapeutics, Inc. | Director | Dec 26, 2024 | D | $30,444,124 similar: $2,000,000–$19,999,994 | $29,868,794 | 30 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Smith Health, Inc. | Director | Feb 15, 2024 | D | $59,999,968 similar: $500,000–$7,000,000 | $59,999,968 | 9 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Accompany Health, Inc. | Director | Feb 2, 2024 | D | $56,309,997 similar: $829,831–$9,999,998 | $56,309,997 | 13 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Venrock Associates X, L.P. group: Venrock | Director Managing Member of the General Partner | Jan 8, 2024 | D | $650,000,000 similar: $155,000–$5,250,000 | $650,000,000 | 176 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Jun 1, 2023 | D | $1,855,000 similar: $2,000,000–$19,999,994 | $1,855,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | JW Celtics Investment Corp. | Director | May 26, 2023 | D | Indefinite similar: $2,000,000–$19,999,994 | $10,999,980 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Jan 18, 2023 | D | $27,791,098 similar: $2,000,000–$19,999,994 | $27,791,098 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Jan 18, 2023 | D | $4,399,977 similar: $2,000,000–$19,999,994 | $4,399,977 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Sep 30, 2022 | D | $35,099,929 similar: $500,000–$7,000,000 | $35,099,929 | 9 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Kelonia Therapeutics, Inc. | Director | Apr 29, 2022 | D | $50,299,983 similar: $2,000,000–$19,999,994 | $50,299,983 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Smith Health, Inc. | Director | Apr 6, 2022 | D | $27,163,747 similar: $500,000–$7,000,000 | $27,163,747 | 31 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Lyra Health, Inc. | Director | Jan 19, 2022 | D | $234,999,956 similar: $500,000–$7,000,000 | $234,999,956 | 4 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Lyra Health, Inc. | Director | Jun 15, 2021 | D | $199,999,931 similar: $500,000–$7,000,000 | $199,999,931 | 28 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Grand Rounds, Inc. | Director | Jun 4, 2021 | D | $15,092,002 similar: $1,120,617–$11,272,500 | $15,092,002 | 9 similar: 3–24 | No minimum reported similar: $10,000–$70,605 |
| EDGAR ↗ | Public Health Co Group, Inc. | Director | Apr 29, 2021 | D | $5,018,297 similar: $829,831–$9,999,998 | $5,018,297 | 2 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Inscripta, Inc. | Director | Apr 14, 2021 | D | $149,999,970 similar: $2,000,000–$19,999,994 | $149,999,970 | 32 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyra Health, Inc. | Director | Jan 28, 2021 | D | $186,700,000 similar: $500,000–$7,000,000 | $186,689,404 | 33 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Sitka, Inc./Delaware | Director | Jan 19, 2021 | D | $14,249,998 similar: $1,100,015–$10,001,163 | $14,249,997 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Venrock Associates IX, L.P. group: Venrock | Director Manager | Jan 14, 2021 | D | $423,450,000 similar: $155,000–$5,250,000 | $423,450,000 | 75 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Nov 30, 2020 | D | $49,999,996 similar: $2,000,000–$19,999,994 | $49,999,996 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Nov 30, 2020 | D | $8,060,048 similar: $2,000,000–$19,999,994 | $8,060,048 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyra Health, Inc. | Director | Aug 25, 2020 | D | $110,000,000 similar: $500,000–$7,000,000 | $109,999,815 | 23 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Mythic Therapeutics, Inc. | Director | Aug 14, 2020 | D | $18,849,989 similar: $2,000,000–$19,999,994 | $18,849,989 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Jun 12, 2020 | D/A | $72,349,909 similar: $500,000–$7,000,000 | $72,349,909 | 18 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Lyra Health, Inc. | Director | Mar 11, 2020 | D | $75,000,000 similar: $500,000–$7,000,000 | $74,999,973 | 19 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Jan 14, 2020 | D/A | $280,000,000 similar: $2,000,000–$19,999,994 | $198,498,007 | 45 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Dec 23, 2019 | D | $42,349,921 similar: $500,000–$7,000,000 | $42,349,921 | 15 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Dec 11, 2019 | D | $124,999,957 similar: $2,000,000–$19,999,994 | $92,149,960 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stride Health, Inc. | Director | Oct 16, 2019 | D | $10,999,988 similar: $829,831–$9,999,998 | $10,999,988 | 8 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Psy Therapeutics, Inc. | Director | Oct 2, 2019 | D | $4,297,692 similar: $829,831–$9,999,998 | $3,967,692 | 19 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Inscripta, Inc. | Director | Apr 15, 2019 | D/A | $49,999,979 similar: $2,000,000–$19,999,994 | $49,999,979 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Mar 15, 2019 | D/A | $23,993,843 similar: $500,000–$7,000,000 | $16,993,843 | 15 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Mar 12, 2019 | D | $150,000,000 similar: $2,000,000–$19,999,994 | $73,125,000 | 30 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Jan 22, 2019 | D | $29,999,981 similar: $2,000,000–$19,999,994 | $25,649,982 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyra Health, Inc. | Director | Dec 17, 2018 | D/A | $70,000,000 similar: $500,000–$7,000,000 | $61,029,561 | 19 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Oct 9, 2018 | D/A | $13,993,851 similar: $500,000–$7,000,000 | $13,993,851 | 15 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Sep 17, 2018 | D | $1,146,592 similar: $2,000,000–$19,999,994 | $1,146,592 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyra Health, Inc. | Director | Jun 25, 2018 | D | $45,000,000 similar: $500,000–$7,000,000 | $44,750,016 | 19 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Apr 18, 2018 | D | $10,000,000 similar: $500,000–$7,000,000 | $9,993,856 | 14 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Mar 7, 2018 | D | $55,499,974 similar: $2,000,000–$19,999,994 | $55,499,974 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Mar 7, 2018 | D | $1,005,358 similar: $2,000,000–$19,999,994 | $1,005,358 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Devoted Health, Inc. | Director | Oct 20, 2017 | D | $61,950,017 similar: $500,000–$7,000,000 | $61,950,017 | 23 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Stride Health, Inc. | Director | Aug 22, 2017 | D | $23,499,983 similar: $500,000–$7,000,000 | $23,499,983 | 9 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Aug 4, 2017 | D/A | $850,000,020 similar: $2,000,000–$19,999,994 | $524,601,480 | 90 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Achaogen Inc | Director | May 16, 2017 | D | $9,999,976 similar: $2,000,000–$19,999,994 | $9,999,976 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Apr 3, 2017 | D/A | $650,000,040 similar: $2,000,000–$19,999,994 | $475,676,760 | 75 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inscripta, Inc. | Director | Mar 1, 2017 | D | $22,999,995 similar: $2,000,000–$19,999,994 | $22,999,995 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Feb 24, 2017 | D | $9,999,916 similar: $500,000–$7,000,000 | $3,999,917 | 15 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Venrock Associates VIII, L.P. group: Venrock | Director Member of the General Partner to Issuer | Feb 9, 2017 | D | $413,600,000 similar: $155,000–$5,250,000 | $413,600,000 | 88 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Jan 13, 2017 | D | $3,594 similar: $2,000,000–$19,999,994 | $3,594 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Jan 6, 2017 | D/A | $650,000,040 similar: $2,000,000–$19,999,994 | $390,689,280 | 38 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Sep 15, 2016 | D | $600,000,000 similar: $2,000,000–$19,999,994 | $184,360,140 | 28 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PowerVision, Inc. | Director | Jul 26, 2016 | D/A | $46,000,000 similar: $829,831–$9,999,998 | $45,064,352 | 18 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Achaogen Inc | Director | Jun 14, 2016 | D | $32,769,984 similar: $2,000,000–$19,999,994 | $25,449,987 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PowerVision, Inc. | Director | Apr 19, 2016 | D/A | $41,000,000 similar: $829,831–$9,999,998 | $40,000,000 | 13 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Kyruus, Inc. | Director | Sep 18, 2015 | D | $36,997,236 similar: $500,000–$7,000,000 | $36,997,236 | 14 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Venrock Associates VII, L.P. group: Venrock | Director Member of the General Partner to Issuer | Aug 6, 2014 | D | $415,565,000 similar: $155,000–$5,250,000 | $415,565,000 | 70 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | May 20, 2014 | D | $20,000,000 similar: $500,000–$7,000,000 | $11,250,000 | 9 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Apr 7, 2014 | D | $200,000,023 similar: $1,694,259–$16,000,000 | $200,000,023 | 38 similar: 1–13 | $14,446 similar: $10,000–$55,000 |
| EDGAR ↗ | Bellerophon Therapeutics, Inc. | Director | Feb 21, 2014 | D | $1 similar: $1,694,259–$16,000,000 | $1 | 4 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | PowerVision, Inc. | Director | Jan 27, 2014 | D | $30,000,000 similar: $829,831–$9,999,998 | $4,000,000 | 9 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Aug 13, 2013 | D | $20,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Achaogen Inc | Director | Mar 22, 2013 | D | $30,683,703 similar: $2,000,000–$19,999,994 | $18,905,707 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | IRONWOOD PHARMACEUTICALS INC group: Ironwood | Director | Jan 10, 2013 | D | $175,000,000 similar: $1,694,259–$16,000,000 | $175,000,000 | 18 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Jan 3, 2013 | D | $11,000,014 similar: $500,000–$7,000,000 | $11,000,014 | 9 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Dec 14, 2012 | D | $13,000,000 similar: $1,694,259–$16,000,000 | $13,000,000 | 16 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Aug 30, 2012 | D/A | $47,523,114 similar: $1,694,259–$16,000,000 | $45,791,354 | 35 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Aug 22, 2012 | D | $7,250,000 similar: $1,694,259–$16,000,000 | $7,250,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Aug 21, 2012 | D | Indefinite similar: $2,000,000–$19,999,994 | $9,244,679 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CASTLIGHT HEALTH, INC. | Director | May 9, 2012 | D | $99,999,969 | $99,999,969 | 35 | No minimum reported |
| EDGAR ↗ | Aria Diagnostics, Inc. | Director | Jan 17, 2012 | D | $52,699,628 similar: $2,000,000–$19,999,994 | $52,699,628 | 26 similar: 2–16 | $1,497 similar: $10,000–$50,000 |
| EDGAR ↗ | PowerVision, Inc. | Director | Dec 22, 2011 | D | $12,500,001 | $12,500,001 | 7 | No minimum reported |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Dec 15, 2011 | D | $15,000,098 similar: $1,694,259–$16,000,000 | $15,000,098 | 19 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Kyruus, Inc. | Director | Nov 8, 2011 | D | $3,100,000 similar: $500,000–$7,000,000 | $2,999,989 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Aug 25, 2011 | D/A | $43,962,606 similar: $1,694,259–$16,000,000 | $40,305,929 | 34 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CODERYTE INC | Director | Jul 29, 2011 | D | $2,817,569 | $2,500,000 | 9 | No minimum reported |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Jun 10, 2011 | D/A | $28,962,606 similar: $1,694,259–$16,000,000 | $27,019,995 | 32 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | PowerVision, Inc. | Director | Apr 22, 2011 | D/A | $24,718,955 | $24,718,955 | 21 | No minimum reported |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Apr 20, 2011 | D | $1,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Apr 20, 2011 | D/A | $35,988,360 similar: $2,000,000–$19,999,994 | $35,988,360 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PowerVision, Inc. | Director | Dec 13, 2010 | D/A | $20,779,946 | $20,529,945 | 20 | No minimum reported |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Nov 19, 2010 | D | $23,999,989 similar: $1,694,259–$16,000,000 | $16,499,994 | 17 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Oct 13, 2010 | D | $1,499,999 similar: $1,694,259–$16,000,000 | $1,499,999 | 15 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Sep 7, 2010 | D | $15,000,000 similar: $1,694,259–$16,000,000 | $5,000,750 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | PowerVision, Inc. | Director | Aug 3, 2010 | D | $20,529,945 | $20,529,945 | 13 | No minimum reported |
| EDGAR ↗ | SURFACE LOGIX INC | Director | Jul 16, 2010 | D | $4,600,000 similar: $2,000,000–$19,999,994 | $3,999,974 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Venrock Partners VI, L.P. group: Venrock | Promoter A Member of the General Partner | Jul 9, 2010 | D | $25,790,817 | $25,790,817 | 28 | No minimum reported |
| EDGAR ↗ | Venrock Associates VI, L.P. group: Venrock | Promoter A Member of the General Partner | Jul 9, 2010 | D | $328,424,183 | $328,424,183 | 59 | No minimum reported |
| EDGAR ↗ | CASTLIGHT HEALTH, INC. | Director | Jun 23, 2010 | D | $59,999,997 | $59,999,997 | 15 | $4,111 |
| EDGAR ↗ | Aria Diagnostics, Inc. | Director | Jun 9, 2010 | D | $12,824,996 similar: $2,000,000–$19,999,994 | $12,500,000 | 7 similar: 2–16 | $5,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Jun 9, 2010 | D | $5,000,000 similar: $1,694,259–$16,000,000 | $5,000,000 | 13 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | May 14, 2010 | D | $16,000,000 similar: $1,694,259–$16,000,000 | $14,488,394 | 30 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Achaogen Inc | Director | Apr 19, 2010 | D | $56,413,706 similar: $2,000,000–$19,999,994 | $35,360,873 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Jan 15, 2010 | D/A | $9,026,189 similar: $1,694,259–$16,000,000 | $9,026,189 | 33 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Dec 24, 2009 | D/A | $32,488,360 similar: $2,000,000–$19,999,994 | $32,488,360 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | INTARCIA THERAPEUTICS, INC | Director | Dec 2, 2009 | D | $8,751,312 similar: $1,694,259–$16,000,000 | $7,005,130 | 10 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Nov 23, 2009 | D | $30,488,360 similar: $2,000,000–$19,999,994 | $30,488,360 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | IRONWOOD PHARMACEUTICALS INC group: Ironwood | Director | Nov 17, 2009 | D | $15,000,018 similar: $1,694,259–$16,000,000 | $15,000,018 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | IKARIA HOLDINGS INC | Director | Oct 2, 2009 | D/A | Indefinite similar: $1,694,259–$16,000,000 | $54,947,203 | 75 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CASTLIGHT HEALTH, INC. | Director | Sep 9, 2009 | D | $17,760,000 | $16,999,999 | 16 | $4,000 |
| EDGAR ↗ | IRONWOOD PHARMACEUTICALS INC group: Ironwood | Director | Sep 3, 2009 | D | $24,999,996 similar: $1,694,259–$16,000,000 | $24,999,996 | 1 similar: 1–13 | $24,999,996 similar: $10,000–$55,000 |
| EDGAR ↗ | IRONWOOD PHARMACEUTICALS INC group: Ironwood | Director | Sep 3, 2009 | D/A | $249,996 similar: $1,694,259–$16,000,000 | $249,996 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | IRONWOOD PHARMACEUTICALS INC group: Ironwood | Director | Aug 31, 2009 | D | $249,996 similar: $1,694,259–$16,000,000 | $249,996 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Jul 27, 2009 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $10,000,000 | 13 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (7 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Bryan Roberts. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Bryan Roberts appears on a new Form D, or when a court case or SEC action is matched to them. See plans →